Stockscreener 앱 받기
47.66
2.06%
-1.00
시간 외 거래:
47.52
-0.14
-0.29%
Sanofi Adr 주식(SNY)의 최신 뉴스
Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz
DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz
Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz
Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness - GlobeNewswire Inc.
How Do Investors Really Feel About Sanofi SA? - Sahm
CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz
BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz
Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz
Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz
RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz
SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz
Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
FDA Refuses To Review Moderna's Influenza Shot Application - Sahm
SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Is Sanofi SA (SNY) One of the Best Cheap Stocks to Buy for 2026 - Finviz
Sanofi Found In Breach Of UK Pharmaceutical Marketing Code Over Beyfortus Claims - Sahm
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Sanofi Plans Regulatory Submission For Investigational Drug For Rare Disease Despite Mixed Data From Pivotal Trials - Sahm
Analysts Have Conflicting Sentiments on These Healthcare Companies: Regeneron (REGN), Resmed (RMD) and Sanofi (OtherSNYNF) - The Globe and Mail
REGN Q4 Earnings Beat Estimates, Sales Rise on Eylea HD Growth - Finviz
European ADRs Slip, But Still End The Week Higher - Finimize
Sanofi ADR earnings beat by $0.69, revenue fell short of estimates - Investing.com South Africa
SNY Stock Today: January 30 RSV Wave in Germany Puts Beyfortus in Focus - Meyka
TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth - Finviz
Earnings call transcript: Sanofi Q4 2025 earnings beat EPS forecast - Investing.com
Earnings Preview: Sanofi - Sahm
Berenberg Bank Remains a Buy on Sanofi (SNY) - Finviz
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
Novavax Grants License for Use of Matrix-M Adjuvant to Pfizer - Finviz
The Truth About Sanofi S.A.: Is This Pharma Giant the Sleeper Stock Everyone’s Sleeping On? - AD HOC NEWS
Sanofi (SNY) Secures Approval for Cablivi in the US and Plozasiran in China - Finviz
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Moderna Stock on the Move: What Sparked the 13% Jump in the Past Week? - Finviz
Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes - Finviz
1.41%
0.83%
자본화:
|
볼륨(24시간):